Sign In
Buy NVG
$12.56
-0.0800 (-0.633%)
At Close: Jun 03, 2026
NVG: Flirting With A Premium Limits Current Appeal
11:59pm, Tuesday, 02'nd Jun 2026
Nuveen AMT-Free Municipal Credit Income Fund now trades at a slight premium, continuing the trend of tighter valuation. NVG's 7.48% yield is high and getting investors' attention, but it continues to
VANCOUVER, British Columbia, May 26, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-cla
MONTREAL, April 15, 2026 /PRNewswire/ -- Vision Marine Technologies Inc. (NASDAQ: VMAR) ("Vision Marine" or the "Company"), a company specializing in high-voltage marine propulsion and a vertically in
VANCOUVER, British Columbia, April 07, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-c
RiverNorth Capital Trims Position in Nuveen AMT-Free Municipal Credit Income Fund
09:42pm, Friday, 13'th Mar 2026
Rivernorth Capital Management reduced Nuveen AMT-Free Municipal Credit Income Fund (NVG) position by 2,033,953 shares Quarter-end position value decreased by $24.89 million, reflecting both trading an
NVG Vs. NZF: Comparing Nuveen Munis I Hold
08:00am, Friday, 13'th Feb 2026
I increased exposure to municipal bond CEFs, adding Nuveen AMT-Free Municipal Credit Income Fund and Nuveen Municipal Credit Income Fund for higher yields. NXP remains a core holding for its high qual
Nuveen AMT-Free Municipal Credit Income Fund (NYSE:NVG) Stock Price Crosses Above Fifty Day Moving Average – Here’s Why
03:30am, Wednesday, 11'th Feb 2026
Nuveen AMT-Free Municipal Credit Income Fund (NYSE: NVG - Get Free Report)'s stock price crossed above its fifty day moving average during trading on Tuesday. The stock has a fifty day moving average
NervGen Pharma Reports Third Quarter Financial Results and Provides Business Updates
07:05am, Monday, 24'th Nov 2025
Expanded CONNECT SCI Study data demonstrated unprecedented durable improvement in function, independence, and quality of life in individuals living with chronic spinal cord injury Completed a U.S. Foo
NVG: Tax Efficiency And High Yield In Municipal Bonds
05:27pm, Tuesday, 23'rd Sep 2025
Nuveen AMT-Free Municipal Credit Income Fund offers a 7.79% yield, monthly distributions, and AMT-free income, appealing to tax-sensitive investors. NVG trades at a 4.85% discount to NAV, below its 10
Demonstrated significant hearing restoration in blast-induced sensorineural hearing loss models Promoted significant functional recovery and axonal regeneration in peripheral nerve injury models Reinf
Vancouver, British Columbia--(Newsfile Corp. - July 1, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neuroreparative therapeutics,
NervGen Pharma: Risky, Yet Promising With Big Upside
09:00am, Friday, 13'th Jun 2025
NervGen Pharma's NVG-291 shows promising early trial results for spinal cord injury, especially in restoring hand function, with strong clinical relevance. Despite a narrow pipeline and high cash burn
NVG: Converting Capital Into Income
12:17pm, Tuesday, 03'rd Jun 2025
NVG is a closed-end municipal bond fund, leveraging credit and interest rate risk to maximize tax-free income for high-income investors. The fund is AMT-free and targets investors facing high federal
Vancouver, British Columbia--(Newsfile Corp. - May 21, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotechnology company dedicated to developing neuroreparative therapeu
NervGen Pharma Reports 2024 Year-End Financial Results and Provides Business Updates
07:30am, Thursday, 03'rd Apr 2025
Completed enrollment in the chronic cohort and commenced enrollment in the subacute cohort of its Phase 1b/2a clinical trial for lead drug candidate, NVG-291, in spinal cord injury (SCI) Initiated an
